Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021
15 juin 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March...
Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update
10 juin 2021 08h00 HE
|
Renalytix AI plc.
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15,...
Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment
07 juin 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK and SALT LAKE CITY, June 07, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced a series of key hires to drive its commercialization strategy in the United...
Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care
03 juin 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced results from a new utility study. The study confirmed the importance of risk assessment...
Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health
19 mai 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK and CHARLOTTE, N.C. and WINSTON-SALEM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), Atrium Health, Wake Forest Baptist Health and Wake Forest School...
U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing
22 avr. 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK, April 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced that the United States Government has granted the company a 10-year Governmentwide...
KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)
20 avr. 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces the findings of a new study in which the commercially available KidneyIntelX test accurately...
RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform
14 avr. 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for patent...
Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions
08 avr. 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces findings presented in a Late-Breaking presentation at the National Kidney Foundation’s 2021 Spring...
Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure
05 avr. 2021 07h00 HE
|
Renalytix AI plc.
NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney...